PLX - Protalix BioTherapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Protalix BioTherapeutics, Inc.

2 Snunit Street
Science Park
Karmiel 21000
972 4 988 9488

Full Time Employees232

Key Executives

Mr. Moshe Manor431.98kN/A61
Dr. Yoseph Shaaltiel Ph.D.343.57kN/A63
Mr. Yossi Maimon CPA, MBA334.85kN/A46
Mr. Tzvi Palash M.Sc., B.Sc.280.84kN/A60
Dr. Einat Brill-Almon Ph.D.300.31kN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Corporate Governance

Protalix BioTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.